Biotech Values

[jmarce]

Homology Medicines (FIXX) sets terms for $100 million IPO

Curious if anyone has been following this one and has thoughts on their approach vs. CRISPR? S-1 is an interesting read with their combination of gene therapy and gene editing approaches but valuation seems rich for pre-clinical (then again, maybe not relative to the CRISPR copmany valuations) and they seem a bit all over the place with the number of potential targets/programs discussed.

Homology Medicines, a preclinical biotech developing a gene therapy delivery platform for rare diseases, announced terms for its IPO on Monday.

The Bedford, MA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Homology Medicines would command a fully diluted market value of $529 million.

Homology Medicines was founded in 2015 and plans to list on the Nasdaq under the symbol FIXX. BofA Merrill Lynch, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. It is expected to price during the week of March 26, 2018.

https://www.renaissancecapital.com/IPO-Center/News/55559/Rare-disease-biotech-Homology-Medicines-sets-terms-for-$100-million-IPO?utm_source=dlvr.it&utm_medium=twitter